Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Polynovo Limited ( (AU:PNV) ) is now available.
PolyNovo Limited announced a strong increase in sales for the first half of FY25, with significant growth in the U.S. and other international markets. The company reported total group revenue of A$59.9 million, a 22.8% increase from the previous year. As PolyNovo expands its NovoSorb platform beyond burns to include plastic and reconstructive surgery, they also progress towards PMA approval with the FDA, aiming to further enhance patient outcomes and industry positioning.
More about Polynovo Limited
PolyNovo Limited is a disruptive medical device company specializing in Advanced Wound Care. The company designs, develops, and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology. Their product range includes applications in breast sling, hernia, and orthopaedic, focusing on providing innovative solutions in dermal regeneration.
YTD Price Performance: 15.38%
Average Trading Volume: 3,484
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $924.3M
For an in-depth examination of PNV stock, go to TipRanks’ Stock Analysis page.
